153 related articles for article (PubMed ID: 36757197)
1. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study.
Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Oppermann U; Chiabudini M; von Weikersthal LF; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
Int J Cancer; 2023 Jul; 153(1):141-152. PubMed ID: 36757197
[TBL] [Abstract][Full Text] [Related]
2. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Chiabudini M; Fischer von Weikersthal L; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
Cancer Med; 2021 Nov; 10(22):8127-8137. PubMed ID: 34668662
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
5. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
6. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
Xu B; Cheng H; Li K; Lv Y; Zeng X; Liu T; Yu W; Guo W
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3029-3038. PubMed ID: 34973080
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
13. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
[TBL] [Abstract][Full Text] [Related]
17. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S
Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
